Ajovy is used for the preventive management of migraine, addressing the frequency and impact of recurrent attacks. This treatment is relevant for the preventive management of migraine in adults and for episodic migraine in pediatric patients aged 6 to 17 who weigh 45 kg or more.

Preventive Management of High-Frequency and Chronic Migraine

This treatment is primarily applied across conditions involving recurrent or episodic manifestations that are frequent, including both chronic migraine and frequent episodic migraine patterns. It is utilized to assist with a reduction in the total number of painful days each month, which supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load.

Reducing Symptoms that Interfere with Daily Functioning

This treatment is applied in clinical settings that involve symptoms that interfere with daily functioning and create noticeable physiological strain. The treatment assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations, and it is relevant for easing the need for frequent use of medications taken during an acute attack.

---

Quick Fact: Management of Recurrent Symptoms

Ajovy is commonly used to help with conditions where symptoms may intensify temporarily, and when supportive symptom management is appropriate.

Who Can and Cannot Use Ajovy (Fremanezumab-vfrm)?

The eligibility for Ajovy is strictly defined by regulatory authorities based on age, hypersensitivity, and physiological status. The medicine is contraindicated in patients with a history of serious hypersensitivity to fremanezumab-vfrm or to any of the formulation's excipients, representing the absolute prohibition to use.

Age-Group Eligibility

Use is established for adults (18 years and older). Safety and effectiveness have not been established in children younger than 6 years of age. In the US, use is restricted to adolescents (6 to 17 years) for episodic migraine only, and is not established for chronic migraine in this age group. European labeling generally does not recommend use in patients under 18. Limited clinical data are available for patients aged 65 and over.

Condition-Based Restrictions

Ajovy has not been studied in patients with severe hepatic impairment or severe renal impairment. While no dose adjustment is required for patients with mild to moderate impairment, use in severe conditions is not established.

Pregnancy and Lactation Status

Due to limited human data, use during pregnancy is generally avoided unless clinically required. It is unknown if the drug is excreted in human milk, and a risk to the nursing infant cannot be excluded.

The official regulatory documents define the interaction profile of fremanezumab-vfrm (Ajovy) by noting its low potential for drug-drug interactions, which is characteristic of its classification as a humanized monoclonal antibody. Unlike many small-molecule drugs, fremanezumab is generally eliminated through non-specific protein catabolism, not through the major metabolic pathways responsible for most medication interactions.

---

Key Interaction Findings

Interaction Classification	Official Regulatory Statement
Metabolic Interactions	No pharmacokinetic drug interactions are expected because fremanezumab-vfrm is not metabolized by Cytochrome P450 (CYP) enzymes.
Exposure Modification	Co-administration with acute migraine treatments, including triptans, analgesics, and ergots, did not affect the systemic exposure (pharmacokinetics) of fremanezumab.

---

Regulatory Restrictions

• Contraindicated Combinations: No specific drug-drug or drug-substance combinations are formally listed as contraindicated due to an interaction risk in regulatory documents.
• Timing Requirements: No mandatory administration timing or separation requirements are documented in the official regulatory label for co-administered medicinal products.
• Other Substances: No explicit interaction information regarding food, alcohol, or herbal products is documented in regulatory prescribing information.

This profile is based on the regulatory conclusion that formal clinical interaction studies were not considered necessary given the predictable catabolic elimination pathway of the drug.

The mechanism of action for Ajovy, which contains fremanezumab-vfrm, centers entirely on blocking the signaling of a key neuropeptide involved in nociceptive signaling.

---

Direct Neutralization of CGRP Ligand

Fremanezumab-vfrm is a specific monoclonal antibody that acts as an antagonist by binding directly to the Calcitonin Gene-Related Peptide (CGRP) ligand . This process, known as ligand sequestration, neutralizes the CGRP molecule and physically prevents it from engaging and activating its receptor (CGRP-R) on sensory neurons and blood vessels. This action modifies the early molecular steps that shape systemic physiological outcomes.

---

Modulation of Trigeminovascular Signaling

By continuously suppressing CGRP-R activation, the mechanism directly modulates the trigeminovascular system and the associated nociceptive signaling pathways. This dampens excessive excitatory input from sensory neurons, thereby facilitating a more regulated state within targeted pathways. The resulting physiological effect is the stabilization of neuronal excitability, which modulates the sensitivity of the nociceptive pathways and modifies the influence of excessive CGRP activity.

Administration Overview

Ajovy is administered as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. Common injection sites include the abdomen, the front of the thighs, or the back of the upper arms. It is important to rotate the injection site with each dose to maintain skin health and avoid injecting into areas that are tender, bruised, red, or hard.

Preparation for Use

Before administration, the medication is typically removed from refrigeration and allowed to reach room temperature. This process generally takes at least 30 minutes, during which the medication should be kept out of direct sunlight. The solution should be inspected through the viewing window of the device; it should appear clear to opalescent and colorless to slightly yellow. If the liquid contains visible particles or appears cloudy, the dose should not be used.

Device Types

There are two primary methods for administering this medication:

• Pre-filled Syringe: A traditional syringe with a needle that is manually inserted and depressed.
• Pre-filled Autoinjector: A device that automates the needle insertion and delivery of the medication once pressed against the skin.

Each device is designed for a single use only. Once the injection is complete, the device must be disposed of in a puncture-resistant sharps container rather than in regular household trash.

Storage and Handling

Proper storage is essential to maintain the stability of the medication. It should be stored in its original carton to protect it from light and kept in a refrigerator. The medication must not be frozen and should not be shaken, as vigorous movement can damage the proteins in the solution.

Research Evidence / Overview of Studies for Ajovy

---

Evidence for Use in Chronic and Episodic Migraine Prevention in Adults

Studies were conducted on Ajovy (fremanezumab-vfrm) in adults with both chronic migraine (15 headache days per month) and episodic migraine (4 to < 15 migraine days per month). The foundational evidence comes from short-term, placebo-controlled randomized controlled trials (RCTs), typically observing responses over a 12-week period. These studies primarily focused on outcomes such as the mean change in Monthly Migraine Days (MMD) and the proportion of patients who achieved a predefined reduction in MMD (e.g., 50% or more).

Findings highlighted changes measured during the study period for both migraine types, including patterns related to the monthly use of acute migraine-specific medications. The compound was also evaluated in subgroups of patients whose conditions involved periods of heightened symptoms due to co-occurring Acute Medication Overuse (AMO).

Long-Term Studies and Gaps

Longer-duration data was gathered through less-controlled extension studies that observed patients for periods up to one or two years. These studies monitored outcomes related to physical discomfort over time to assess sustained patterns. However, since the most rigorous, controlled evidence is limited to the initial short-term phases, long-term effects are not fully established by the same high-quality research designs. Comparative evidence remains insufficient for certain complex patient groups.

Evidence for Use in Pediatric Episodic Migraine Prevention

Research has also explored the compound in a younger population for episodic migraine (ages 6 to 17 years and weighing 45 kg or more). These studies consisted of smaller, placebo-controlled RCTs that assessed outcomes like the change in the Monthly Average Number of Migraine Days over 12 weeks. The studies contributed to understanding short-term changes in this population. Evidence is limited compared to adults, particularly regarding long-term outcomes, and data for pediatric patients with chronic migraine remains insufficient.

Common questions about Ajovy (FAQ)

Q: How long does it typically take to feel the effects of Ajovy?

Studies used for the authorization of Ajovy typically assessed changes in the number of monthly migraine days beginning with the first month of treatment. These foundational placebo-controlled trials often observed and measured treatment effects over a period of 12 weeks, which is about three months.

Q: What happens if I miss a scheduled dose of Ajovy?

Official product information describes that if a dose is missed, it can be administered as soon as possible. Subsequent doses should then be scheduled from the date of the most recent injection to maintain the proper monthly or quarterly schedule. The product information states that a double dose should not be used to make up for a missed dose.

Q: Can Ajovy interact with common over-the-counter pain relievers?

Due to its elimination pathway, Ajovy is not expected to cause pharmacokinetic drug interactions with many small-molecule drugs, including common pain relievers. Clinical studies indicated that using acute migraine treatments like analgesics alongside Ajovy did not affect the level of fremanezumab in the body.

Q: Are there any known interactions between Ajovy and herbal supplements?

Official regulatory documents, such as the FDA and EMA labels, do not provide explicit interaction information regarding herbal products, food, or alcohol. The medicine has a low potential for drug-drug interactions due to how it is processed by the body.

Q: What should I do if the Ajovy liquid looks cloudy or discolored?

The official administration protocol requires you to visually inspect the injection device before use. The solution should appear clear to slightly yellow and must be free of particles. If the liquid is cloudy, discolored, or contains particles, the regulatory guidance states it should be discarded and not used.

Q: Are there known weight changes associated with the use of Ajovy?

Weight gain or weight loss is not listed among the very common, common, or uncommon side effects reported in clinical trials for Ajovy. Official safety information focuses on injection site reactions and the potential for hypersensitivity reactions.

Q: What information is available about Ajovy use in breastfeeding mothers?

Official information states that it is unknown if the active ingredient, fremanezumab-vfrm, is excreted into human milk. Due to the limited human data, a potential risk to a nursing infant cannot be excluded, and this is noted in regulatory documents.

Q: Are there any specific patient groups that show a better response to Ajovy in studies?

Clinical trials included analyses of specific patient groups, such as those with Acute Medication Overuse. Results were generally consistent with the overall study population, indicating the drug showed effectiveness in this group, which is often difficult to treat.

Q: Can Ajovy cause tiredness or fatigue?

Tiredness or fatigue is not listed among the very common, common, or uncommon adverse reactions reported in clinical trials for Ajovy. The safety profile is primarily characterized by local adverse events at the injection site.

Q: Are there any common reasons why Ajovy might not be prescribed?

The medicine is strictly contraindicated (must not be used) if a patient has a known history of serious hypersensitivity to fremanezumab-vfrm or to any of its inactive ingredients. Additionally, safety has not been established in children under six or in adults with severe renal or hepatic impairment.

Q: Is it possible to develop a tolerance to Ajovy over time?

Clinical trials monitored for the development of anti-drug antibodies (ADAs), which are proteins the body produces against the medicine. The presence of these antibodies did not appear to impact the drug’s effectiveness or safety over the short-term study periods.

Q: Is Ajovy safe to use during pregnancy, according to official information?

Due to limited human data, official information notes that use during pregnancy is generally avoided. The decision to use it requires careful consideration. The manufacturer maintains a pregnancy exposure registry to monitor outcomes.

Q: Can Ajovy affect my ability to drive or operate machinery?

Official regulatory information, such as the European Summary of Product Characteristics, states that Ajovy has no known influence on the ability to drive or operate machinery.

Q: Are there any official recommendations regarding alcohol consumption while on Ajovy?

Official regulatory documents do not provide explicit interaction information regarding alcohol consumption. The product’s mechanism of action does not involve the major metabolic pathways that often lead to interactions with alcohol.

Q: Can Ajovy interact with birth control pills?

Ajovy is a monoclonal antibody and is generally eliminated through protein breakdown, not through the major liver enzymes responsible for metabolizing most oral medications, including hormonal contraceptives. Therefore, pharmacokinetic drug interactions with birth control pills are not expected.

Q: What is the most frequently reported side effect of Ajovy in clinical trials?

The most frequently reported adverse reactions (classified as Very Common, meaning ge 1/10) in clinical trials are reactions occurring at the injection site. These include injection site pain, induration (hardening), and erythema (reddening).

Q: Does Ajovy interact with blood pressure medications?

Ajovy is not expected to have pharmacokinetic interactions with blood pressure medications because it is not metabolized by the common liver enzymes. However, postmarketing surveillance has noted rare cases of new-onset or worsening high blood pressure (hypertension) associated with the use of CGRP antagonists.

Q: How quickly does Ajovy leave the body after the last dose?

The medicine has a long duration of action due to its extended elimination half-life, which is the time it takes for half the drug to be cleared from the bloodstream. Regulatory documents estimate this half-life to be approximately 31 days.

Q: Are there official registry programs for monitoring Ajovy users?

Yes, official documentation describes a pregnancy exposure registry. This registry is maintained to actively monitor and collect information on outcomes in women who become pregnant while undergoing treatment with Ajovy.

Q: Is Ajovy only for people who have failed other migraine treatments?

Ajovy is authorized for the preventive treatment of migraine in adults who have at least four migraine days per month, according to the official indication. The authorization is not exclusively for people who have failed other treatments.

Q: Do official materials describe Ajovy affecting the immune system?

Official documentation notes that Ajovy is a humanized monoclonal antibody, and clinical trials monitored for the development of anti-drug antibodies (ADAs). The presence of these antibodies did not appear to affect the medicine's effectiveness or safety over the short-term study periods.

Q: Can Ajovy cause changes in vision?

Changes in vision are not listed among the very common, common, or uncommon adverse reactions reported in clinical trials for Ajovy. Official safety information focuses on reactions at the injection site and the potential for hypersensitivity.

Q: Are there official warnings about combining Ajovy with psychiatric medications?

Ajovy is not expected to have pharmacokinetic drug interactions with psychiatric medications because it is not metabolized by the major liver enzymes that break down most oral medicines. The core regulatory label does not specifically address this combination beyond the general low interaction potential.

Q: How long does a course of Ajovy treatment typically last, according to studies?

The foundational evidence for the drug's authorization comes from short-term, placebo-controlled trials that lasted for 12 weeks (3 months). Longer extension studies have been conducted to observe patients for up to one year to assess the sustained patterns and long-term tolerability.

Q: Can Ajovy be used to treat cluster headaches?

Official regulatory documents clearly state that Ajovy is indicated only for the preventive treatment of migraine in adults. Its use for cluster headaches is not part of the current regulatory approval.

Q: Are the research findings on Ajovy generally considered consistent across different trials?

The regulatory assessment of Ajovy is based on the results of multiple, large, placebo-controlled clinical trials, including those for both episodic and chronic migraine. These results collectively supported the authorization of the drug for its indicated uses.

Q: Does Ajovy contain any common allergens?

Ajovy contains the active ingredient fremanezumab-vfrm and several inactive ingredients (excipients), including L-histidine, polysorbate 80, and sucrose. It is strictly prohibited for use in patients with a serious hypersensitivity reaction to fremanezumab-vfrm or to any of these excipients.

Q: Do official documents mention any effects of Ajovy on mental health?

Official regulatory documents do not list any mental health or psychiatric conditions, such as anxiety or depression, among the very common, common, or uncommon adverse reactions reported in clinical trials for Ajovy.

Q: Is Ajovy used for any conditions besides migraines?

Official regulatory information states that Ajovy is indicated only for the preventive treatment of migraine in adults. Its use is not approved for any other conditions.

Q: What is the shelf life of Ajovy once it is refrigerated?

Ajovy must be stored in the refrigerator in its original carton. The overall shelf life is marked by the expiration date printed on the carton. It must not be used past this date.

Storage and Disposal of Ajovy (fremanezumab-vfrm)

Ajovy must be stored in the original carton to protect it from light and kept refrigerated at a temperature of 36 F to 46 F (2 C to 8 C). The product must not be frozen or shaken. If Ajovy freezes, it must be discarded.

Stability Constraints

If removed from the refrigerator, Ajovy may be stored at room temperature, up to 86 F (30 C), for a maximum of seven days. Once stored at room temperature, the product must not be returned to the refrigerator. It must be discarded if it remains unrefrigerated for longer than seven days.

Disposal and Child Safety

The autoinjector and syringe must be kept out of the reach of small children. Used autoinjectors and syringes are considered sharps and must be disposed of immediately in an FDA-cleared sharps disposal container. Any unused or expired medicine must be disposed of in accordance with local regulatory requirements.